Candel therapeutics reports fourth quarter and full year 2022 financial results and recent corporate highlights

Needham, mass., march 30, 2023 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended december 31, 2022 and provided a corporate update.
CADL Ratings Summary
CADL Quant Ranking